Core Points - Recently, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary, Shanghai Zhaohui Pharmaceutical Co., Ltd., has had its drug registration application for Compound Polyethylene Glycol (3350) Electrolyte Powder accepted by the National Medical Products Administration [1] Group 1 - The drug registration application pertains to a specific product, Compound Polyethylene Glycol (3350) Electrolyte Powder [1] - The acceptance of the application by the regulatory authority indicates a step forward in the product's market entry process [1]

Core Viewpoint - Fosun Pharma's subsidiary Shanghai Chaohui Pharmaceutical has received acceptance for the drug registration application of Compound Polyethylene Glycol (3350) Electrolyte Powder by the National Medical Products Administration, indicating progress in the company's product pipeline for treating chronic constipation [1] Group 1 - The drug is classified as a chemical medication intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1]

Group 1 - Shengxin Lithium Energy signed a framework agreement with Huayou Cobalt for the procurement of 221,400 tons of lithium salt products over five years [1] - Wehua New Materials' subsidiary plans to acquire 70% of He Yutai for 154 million yuan [1] - Xiamen Tungsten plans to invest 600 million yuan to establish a wholly-owned subsidiary for a project with an annual production capacity of 50,000 tons of high-performance battery materials [1][2] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 200-300 million USD for two VLCCs [3] - Hailianxun's stock will resume trading on November 19 after the end of the acquisition request period [5] - Yunnan Energy Investment obtained the development rights for a 25,000 kW wind power project [7] Group 3 - China Resources Double Crane's subsidiary received a drug registration certificate for Oxcarbazepine tablets [8] - Jincheng Pharmaceutical's subsidiary received a CEP certificate for glutathione raw materials [9] - Jinkong Electric plans to transfer 51% of Tongying Thermal Power to an affiliate for 266 million yuan [9] Group 4 - Clean Technology's subsidiary won a bid for a waste incineration power generation project in Thailand with a total investment of up to 4.27 million USD [12] - Tonglian Precision's shareholders set the transfer price for shares at 43.67 yuan each [13] - Hu Nong Commercial Bank's executives collectively purchased 259,100 shares of the company [13] Group 5 - Huatai Medical's subsidiary obtained a medical device registration certificate for polyethylene embolization microspheres [13] - Fosun Pharma's subsidiary's drug registration application was accepted by the National Medical Products Administration [13] - Xianhui Technology signed contracts worth 796 million yuan with multiple subsidiaries of CATL [15] Group 6 - Ningbo Fangzheng signed a strategic cooperation agreement with Huaxiang Qiyuan for the development of various robotic technologies [15] - Ruida Futures' vice president resigned for personal reasons [16] - Samsung Medical is expected to win contracts worth approximately 125 million yuan from the State Grid [17] Group 7 - Tianjin Pharmaceutical's injectable methylprednisolone sodium succinate received registration from Panama's Ministry of Health [19] - Yaxing Anchor Chain plans to invest up to 300 million yuan in a project for deep-sea floating equipment [20] - Zejing Pharmaceutical's clinical trial for ZG006 was approved by the National Medical Products Administration [21] Group 8 - Weiye Co., Ltd. won a bid for a project worth approximately 2.086 billion yuan [23] - Ruimao Tong plans to sell 8.5794 million repurchased shares [25] - Guangge Technology's shareholders plan to reduce their holdings by up to 3.99% [26] Group 9 - Hongsheng Development signed a debt restructuring contract for a total of 2 billion yuan [27][28] - Yatai Co., Ltd. plans to reduce its holdings by up to 1% [30] - Dexin Technology's shareholder plans to reduce its holdings by up to 1% [31] Group 10 - Yaji International's shareholder plans to reduce its holdings by up to 1% [33] - Shenzhen New Star's subsidiary received approval for trial production of a boron trifluoride project [35] - Shengyi Electronics plans to raise up to 2.6 billion yuan through a private placement [36]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has had its drug registration application for Compound Polyethylene Glycol (3350) Electrolyte Powder accepted by the National Medical Products Administration of China [1] Group 1: Drug Information - The drug is intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1] - The total R&D investment for the series of Compound Polyethylene Glycol Electrolyte Powder, including this drug, is approximately RMB 6.21 million as of October 2025 [1] Group 2: Market Potential - According to IQVIA CHPA, the sales revenue of Compound Polyethylene Glycol Electrolyte Powder in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 873 million in 2024 [1] Group 3: Regulatory Status - The drug must obtain drug registration approval and fulfill other requirements before commercial production can commence [1] - The acceptance of the drug registration application is not expected to have a significant impact on the company's current performance [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has had its drug registration application for Compound Polyethylene Glycol (3350) Electrolyte Powder accepted by the National Medical Products Administration of China, indicating progress in the commercialization of this product for chronic constipation treatment [1][1]. Group 1: Company Developments - The drug is intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1]. - As of October 2025, the total R&D investment for the series of Compound Polyethylene Glycol Electrolyte Powder products, including this drug, is approximately RMB 6.21 million (unaudited) [1]. - The acceptance of the drug registration application is not expected to have a significant impact on the company's current performance [1]. Group 2: Market Potential - According to the latest data from IQVIA CHPA, the sales revenue of Compound Polyethylene Glycol Electrolyte Powder in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be approximately RMB 873 million in 2024 [1].

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has had its drug registration application for Compound Polyethylene Glycol (3350) Electrolyte Powder accepted by the National Medical Products Administration of China [1] Group 1: Drug Information - The drug is intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1] - The total R&D investment for the series of Compound Polyethylene Glycol Electrolyte Powders, including this drug, is approximately RMB 6.21 million as of October 2025 [1] Group 2: Market Potential - According to IQVIA CHPA, the sales revenue of Compound Polyethylene Glycol Electrolyte Powder in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 873 million in 2024 [1] Group 3: Regulatory Status - The drug must obtain drug registration approval and fulfill other requirements before commercial production can commence [1] - The acceptance of the drug registration application is not expected to have a significant impact on the company's current performance [1]

Core Viewpoint - Fosun Pharma's subsidiary Shanghai Chaohui Pharmaceutical has received acceptance for the drug registration application of Compound Polyethylene Glycol (3350) Electrolyte Powder by the National Medical Products Administration [1] Group 1: Drug Development - The Compound Polyethylene Glycol (3350) Electrolyte Powder is a chemical drug intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1] - As of October 2025, the group has invested approximately RMB 6.21 million (unaudited) in the research and development of the Compound Polyethylene Glycol Electrolyte Powder series, including this drug [1]

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 董事長 陳玉卿 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司藥品註冊申請獲受理的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 中國，上海 2025 年1 1 月1 8 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * ...

根据 IQVIA CHPA 最新数据1，2024 年，复方聚乙二醇电解质散于中国境内（不 包括港澳台地区）的销售额约为人民币 8.73 亿元。 证券代码：600196 股票简称：复星医药 编号：临 2025-177 上海复星医药（集团）股份有限公司 关于控股子公司药品注册申请获受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公 司上海朝晖药业有限公司就复方聚乙二醇（3350）电解质散（以下简称"该药品"） 的药品注册申请获国家药品监督管理局受理。 二、该药品的基本信息及研究情况 复方聚乙二醇（3350）电解质散系化学药品，拟用于慢性便秘症（器质性疾病 引起的便秘除外）。 截至 2025 年 10 月，本集团（即本公司及控股子公司/单位，下同）现阶段针对 包括该药品在内的复方聚乙二醇电解质散系列药品的累计研发投入约为人民币 621 万元（未经审计）。 三、风险提示 二零二五年十一月十八日 该药品在进行商业化生产前，尚需（其中主要包括）获得药品 ...

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has received acceptance for the drug registration application of Compound Polyethylene Glycol (3350) Electrolyte Powder by the National Medical Products Administration, indicating a significant step in expanding its product portfolio in the chronic constipation treatment market [1] Group 1: Company Developments - The drug is intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1] - The acceptance of the drug registration application marks a crucial milestone for the company in the pharmaceutical sector [1] Group 2: Market Potential - According to IQVIA CHPA data, the projected sales revenue for Compound Polyethylene Glycol Electrolyte Powder in mainland China (excluding Hong Kong, Macau, and Taiwan) is approximately RMB 873 million in 2024 [1]